卵巢癌是女性生殖系统常见的恶性肿瘤,经常保持隐藏,直到它达到一个高级阶段。标准治疗方案包括卵巢癌细胞减灭术加术后巩固化疗和维持治疗,尽管它有很高的复发率。在治疗期间,化疗会导致骨髓抑制,一种称为化疗诱导的骨髓抑制(CIM)的疾病。这种抑制可能需要剂量减少或化疗治疗周期延迟。在严重的情况下,CIM会导致感染,发烧,以及对患者生命的潜在危害。这里,我们报道了1例卵巢恶性肿瘤生化复发的女性患者,该患者接受了化疗联合Trilaciclib治疗,先前的围手术期化疗后发生严重的M。化疗前静脉注射Trilaciclib,这显著减轻了化疗的副作用,减少严重CIM的发生,提高患者的生活质量,减轻了住院的经济负担。我们希望该病例的回顾性分析可以为某些恶性肿瘤患者在化疗期间预防和治疗严重的M提供参考。最终使更多的肿瘤患者受益。
Ovarian cancer is a prevalent malignant tumor of the female reproductive system, often remaining concealed until it reaches an advanced stage. The standard treatment protocol includes cytoreductive surgery for ovarian cancer plus postoperative consolidation chemotherapy and maintenance therapy, although it carries a high recurrence rate. During the treatment period, chemotherapy can lead to bone marrow suppression, a condition known as Chemotherapy-Induced Myelosuppression (CIM). This suppression may necessitate dose reduction or chemotherapy treatment cycle delay. In severe cases, CIM can result in infection, fever, and potential harm to the patient\'s life. Here, we report a
case of a female patient with ovarian malignant tumor of biochemical recurrence who treated with chemotherapy combined with Trilaciclib, following previous perioperative chemotherapy with occurrence of severe CIM. It involves an intravenous injection of Trilaciclib before chemotherapy, which significantly abates the side effects of chemotherapy, reduces the occurrence of severe CIM, improves the patients\' quality of life, and decreases the economic burden of hospitalization. We hope that this retrospective analysis of the
case may serve as a reference in preventing and treating severe CIM during chemotherapy in some patients with malignant tumors, ultimately benefiting more patients with tumors.